Astellas Pharma (OTCMKTS:ALPMY) Posts Earnings Results, Beats Estimates By $0.15 EPS

Astellas Pharma (OTCMKTS:ALPMY) announced its earnings results on Wednesday. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.29 by $0.15, Zacks reports. The firm had revenue of $3.67 billion for the quarter, compared to analysts’ expectations of $3.21 billion. Astellas Pharma had a return on equity of 24.24% and a net margin of 15.63%.

Astellas Pharma Price Performance

Shares of OTCMKTS ALPMY traded up $0.20 during mid-day trading on Friday, hitting $15.70. 20,688 shares of the company traded hands, compared to its average volume of 122,311. The company has a current ratio of 1.03, a quick ratio of 0.80 and a debt-to-equity ratio of 0.20. Astellas Pharma has a 1 year low of $8.37 and a 1 year high of $16.19. The business has a 50 day moving average of $13.67 and a two-hundred day moving average of $12.00.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Zacks Research downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Citigroup lowered Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, January 19th. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold”.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).